VEGFA and cervical carcinoma: In patients with advanced, metastatic or recurrent cervical cancer immunotherapies such as bevacizumab, an anti‐VEGF antibody to inhibit angiogenesis [52, 53], and pembrolizumab, an anti‐PD1 antibody [54], are approved as targeted therapies in combination with a platinum‐based chemotherapy.